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Background: Heterogeneity regarding clinical and laboratory ﬁndings at diagnosis of acute
lymphoblastic leukemia exists. The frequency of complete blood count abnormalities and
its  combinations, symptoms and physical ﬁndings were investigated in Hispanic children
from  an open population at the diagnosis of acute lymphoblastic leukemia.
Methods: The patient charts and electronic records of under 16-year-old children diagnosed
with acute lymphoblastic leukemia over 10 years at a regional hematology center of a uni-
versity hospital were analyzed to retrieve data concerning the complete blood count at ﬁrst
evaluation. Type and distribution of abnormal data, frequency of symptoms and physical
ﬁndings at presentation were documented.
Results: The records of 203 children aged 0–15 years diagnosed with acute lymphoblastic
leukemia from 2006 to 2016 were revisited. The results of the blood workup showed a
median white blood cell count of 7120 × 109/L (range: 450–600,000 × 109/L), and a median
hemoglobin concentration of 7.5 g/dL (range: 2.4–15.3 g/dL), whereas the median platelet
count was 47,400 × 109/L (range: 4000–544,000 × 109/L). Leukocytosis and leukopenia were
present in 36.6% and 36.1% of cases, respectively; anemia was diagnosed in 82.9% chil-
dren. The order of frequency for major clinical symptoms was fatigue 62%, fever 60%, bone
and  joint pain 39%, hyporexia 33% and weight loss 21%, while main physical ﬁndings were
hepatomegaly 78%, splenomegaly 63%, lymphadenopathy 57%, pallor 48%, and purpura 30%.
Conclusion: Data differing from those classically expected at diagnosis of acute lymphoblas-
tic leukemia in children were documented in a cohort of Hispanic children over one decade
with a wide spectrum of complete blood count abnormalities, forms of presentation and
frequency of physical ﬁndings.© 2018 Associac¸a˜o Bra
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Table 1 – Initial complete blood count values in 203
children diagnosed with B-cell acute lymphoblastic
leukemia at the Dr. José E. González University Hospital,
in Monterrey, México.
Parameter n (%)
Hemoglobin (g/dL)
Median (range) 7.5 (2.4–15.3)
<11 170 (82.9)
11–14 32 (15.6)
>14 1 (0.5)
White blood cells (×109/L)
Median (range) 7120 (450–600,000)
<4500 74 (36.1)
4500–14,500 52 (25.4)
>14,500 75 (36.6)
Platelets (×109/L)
Median (range) 47,400 (4000–544,000)58  hematol transfus ce
Introduction
Worldwide, around 240,000 new cases of childhood acute
leukemia are diagnosed each year. Acute lymphoblastic
leukemia (ALL) is the most common type of leukemia among
pediatric patients with 75% of cases occurring in developing
countries. It represents 76% of leukemias in under 15-year-old
patients and 30% of all kinds of cancer in this age group.1 The
survival rate of pediatric ALL patients in industrialized coun-
tries has improved to approximately 90% in recent years,2,3
with a 93% overall survival recently reported in the United
States.4 However, in low- and middle-income nations over-
all survival varies from 50% to 75%.5 This difference is due
to, among other reasons, a delay in the diagnosis and subse-
quently in the initiation of treatment.6
Risk stratiﬁcation is pivotal for ALL prognosis and indi-
vidualized therapy.7 According to the criteria of the National
Cancer Institute (NCI), the following features are deter-
minants of high-risk disease: age <1 year or >10 years,
initial white blood cell (WBC) count >50 × 109/L, T-cell ALL
(T-ALL), initial central nervous system leukemia (CNSL),
slow response to induction chemotherapy, breakpoint clus-
ter region-Abelson murine leukemia (BCR-ABL)/mixed-lineage
leukemia (MLL)-AF4 positivity, testicular inﬁltration, lym-
phadenopathy, splenomegaly and hepatomegaly.8–12
Acute leukemia is frequently accompanied by anemia, a
common clinical complication that is responsible for several
symptoms such as fatigue.13 The typical textbook presenta-
tion of ALL consists of normocytic normochromic anemia,
increased or, less frequently, decreased WBC  count, neutrope-
nia and/or the presence of blasts, and thrombocytopenia.10
Opportune diagnosis leads to fast treatment. Thus, it is of
critical importance to recognize symptoms early, the pres-
ence of speciﬁc physical ﬁndings, and to interpret the CBC
correctly. Studies that center exclusively on the initial ﬁnd-
ings at the diagnosis of leukemia are scarce. We were unable
to ﬁnd recent information focused on detailed analysis of CBC
abnormalities, signs and symptoms, and physical ﬁndings in
children with newly  diagnosed ALL, therefore this report ana-
lyzed these data in patients treated at an academic institution
over a 10-year period.
Methods
CBC data, signs, symptoms and physical ﬁndings of 203
consecutive patients diagnosed with ALL attending the Hema-
tology Department of Dr. José E. González University Hospital,
School of Medicine, Universidad Autónoma de Nuevo León
in Monterrey, México from 2006 to 2016 were retrospectively
reviewed for this study. Both, patient charts and electronic
databases were scrutinized. The variables included were age,
gender, WBC  count and differential leukocyte counts, platelet
count and hemoglobin concentration, and their distributions
in the context of clinical symptoms, physical ﬁndings, and
ﬁnal ﬂow cytometry conﬁrming ALL. The Statistical Pack-
age for the Social Sciences (IBM SPSS for Windows, Version
22.0. Armonk, NY: IBM Corp) was used for data analysis. Vari-
ables were stratiﬁed according to risk categories including<150,000 170 (82.9)
≥150,000 33 (16.1)
age (≤1, 2–9 and ≥10 years), hemoglobin (Hb – <11, 11–14
and >14 g/dL), WBC  count (<4500 × 109/L, 4500–14,500 × 109/L
and >14,500 × 109/L), and platelet count (<150,000 × 109/L and
≥150,000 × 109/L). Due to age heterogeneity, ranges of refer-
ence blood count values considered normal for each age group
were used.14 The protocol of the study was approved by the
Institutional Review Board.
Results
Data from 203 children with ALL were studied. Median age at
diagnosis was six years (range: 0–15). The prevalent age group
was 2–9 years (63%). Children <1 year and ≥10 years of age
accounted for 7% and 30% of the cohort, respectively. Male
gender predominated slightly at 52% of the total.
Median values for hematologic parameters were
hemoglobin 7.5 g/dL (range: 2.4–15.3 g/dL); leukocytes:
7120 × 109/L (range: 450–600,000 × 109/L) and platelets:
47,400 × 109/L (range: 4000–544,000 × 109/L). Anemia (Hb
<11.0 g/dL) and thrombocytopenia (platelets <150,000 × 109/L)
at diagnosis were each found in 83% (170) of the cases,
leukocytosis (WBC >14,500 × 109/L) in 36.6% (75 cases) and
leucopoenia in 36.1% (74 cases). Results are summarized in
Table 1.
Bicytopenia plus leukocytosis was found in 27.1% of ALL
children, whereas bicytopenia plus leucopoenia was present
in 26.6%, and bicytopenia plus a normal leukocyte count in
17.2%; frequencies for additional isolated and combined CBC
ﬁndings are shown in Table 2.
The most frequent symptoms were fatigue in 62%, fever
60%, bone and joint pain 39%, hyporexia 33% and weight
loss in 21%. Physical examination at diagnosis revealed hep-
atomegaly in 78%, splenomegaly in 63%, lymphadenopathy
in 57%, pallor in 48%, and purpura in 30%. These results are
shown in Table 3.Discussion
The aim of this study was to document the initial data
that hematologists ﬁnd in children diagnosed with ALL. Our
hematol transfus cell ther
Table 2 – Complete blood count abnormalities in 203
Hispanic children newly  diagnosed with acute
lymphoblastic leukemia.
Complete blood count ﬁnding n (%)
Anemia + leukocytosis + thrombocytopenia 55 (27.1)
Anemia + leukopenia + thrombocytopenia 54 (26.6)
Anemia + thrombocytopenia 35 (17.2)
Anemia + leukopenia 11 (5.4)
Leukocytosis + thrombocytopenia 11 (5.4)
Anemia 9 (4.4)
Thrombocytopenia 8 (3.9)
Leucopenia + thrombocytopenia 7 (3.4)
Anemia + leukocytosis 6 (3)
Leukocytosis 3 (1.5)
Leukopenia 2 (1)
No ﬁndingsa 2 (1)
a Two children were referred to our center due to clinically sug-
gestive symptoms, positive physical examination ﬁndings and a
normal complete blood count.
Table 3 – Symptoms and physical ﬁndings in 203
children diagnosed with acute lymphoblastic leukemia
at the Dr. José E. González University Hospital, in
Monterrey, México.
Clinical symptoms %
Fatigue 62
Fever 60
Bone and joint pain 39
Hyporexia 33
Weight loss 21
Physical examination
Hepatomegaly 78
Splenomegaly 63
Lymphadenopathy 57
Pallor 48
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symptoms and signs or abnormal CBC results. None of the
children in that study were ultimately found to have cancer;Purpura 30
ypothesis was that ﬁndings differ from those traditionally
xpected. Interestingly, there is a lack of studies in contempo-
ary literature speciﬁcally dealing with type and frequency of
BC variables, symptoms and physical examination ﬁndings
dentiﬁed at this early stage in the course of ALL.
The correct interpretation of CBC results, knowledge of
arly symptoms and detection of key signs during physical
xamination are essential for a timely diagnosis of childhood
LL, maximizing the opportunity for cure, and thus it is con-
iderably relevant to be aware of the variable spectrum of these
ata.
There are interesting ﬁndings in this study of over 200
hildren with a conﬁrmed diagnosis of ALL. More  fre-
uently expected CBC ﬁndings, consisting of leukocytosis plus
icytopenia,10 were found in only about 1 in 4 cases (27%);
nterestingly, anemia, present in 83% of the current cohort,
as one of the most frequent CBC abnormalities. This was the
ame percentage as for thrombocytopenia, although in differ-
nt patients. Leukocytosis, alone or combined with another
bnormality, was considerably less frequent, in only 37% of
he children and almost the same as its opposite, leucopenia,
hich was found in 36.5% of the cases.. 2 0 1 9;4  1(1):57–61 59
On the other hand, positive physical ﬁndings were present
in almost 4 of every 5 children, emphasizing the importance
of these in the diagnostic process, essential for suspicion and
for initiating conﬁrmatory clinical and laboratory work-ups.
Median age at diagnosis was six years and males pre-
dominated slightly; studies in Pakistan and Brazil reported
similar results.3,15 Age at diagnosis differed signiﬁcantly from
that observed in high-income countries, including the United
States, with a peak incidence of children from 1 to 4 years of
age.16 Germany, where the peak age is between 1 and 5 years17
and Korea, with a mean age of 3.8 ± 2.3 years.18
The relationship between Hb at diagnosis and prognosis
of ALL is controversial and there is scarce information on
this particular point. At the beginning of the 1980s a group
of hematologists reported that a high WBC  count accom-
panied by a high Hb concentration was associated with a
poorer outlook, apparently because this group of children had
a rapidly multiplying leukemic clone, presenting clinical man-
ifestations before the Hb concentration had time to drop.19
Recently, however, another group found that precursor B-cell
leukemia has a more  favorable prognosis if a higher Hb level
is present. The investigators suggested that patients with a
high Hb concentration were diagnosed at an early stage of dis-
ease and were, therefore, more  susceptible to successful early
chemotherapeutic interventions.20 This apparent discrepancy
appears to reﬂect both a greater awareness of the diagnosis of
ALL and the increase in the success rate of curing ALL with
contemporary chemotherapy regimens reached in the period
spanning over two and a half decades between these reports.
Anemia at diagnosis was present in most of our patients.
This ﬁnding could be related to late diagnosis, since it is con-
siderably higher than that reported in studies from developed
countries. In this respect, in a recent study, anemia was diag-
nosed in 85% of cases, almost the same proportion as the
present research, but with a higher mean hemoglobin con-
centration of 8.4 g/dL vs. 7.5 g/dL in this cohort.3 The normal
range of the WBC  count during childhood is considered to be
4.0–14.5 × 109/L14; almost 30% of the children in our group had
values within this range. This could delay early diagnosis of
ALL if physicians expect to ﬁnd considerably higher or lower
WBC counts.
Few studies report the frequency of physical ﬁndings. In the
current cohort, physical ﬁndings were present in 8 of every 10
children, underscoring the critical importance of a detailed
physical examination as an essential part of ALL diagnosis.
Interestingly hepatomegaly was the most common abnormal-
ity in almost 80%, predominating over lymphadenopathy and
splenomegaly, both present in about 60%. Physical abnormal-
ities reported in a previous study were hepatomegaly and
splenomegaly, in about two-thirds, and lymphadenopathy in
only one quarter of cases15; similar ﬁndings were reported
recently in which hepatomegaly and splenomegaly predomi-
nated in about 60% of cases.2 One important challenge for the
hematologist is that lymphadenopathy is a non-speciﬁc sign.
In one study, it was the most common reason for urgent refer-
ral to assess malignancy, but often without supporting clinicalthen in the absence of high-risk features, a rigorous approach
to evaluating lymphadenopathy in primary care including an
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urgent CBC to investigate leukemia is recommended.21 Impor-
tantly, this study found lymphadenopathy in almost 60% of
children newly  diagnosed with ALL.
Fatigue and fever were the most common symptoms in our
cohort. In a recent study, signs and symptoms were analyzed
in 128 cases before the diagnosis of ALL. The most frequent
ﬁnding was pallor (83% vs. 42% in this cohort), followed by
hyporexia (73% vs. 33%), weight loss (62% vs. 21%), purpura
(39% vs. 30%), fever (27% vs. 60%), and fatigue (23% vs. 62%),
among other less common ﬁndings.22 This demonstrates the
considerable heterogeneity in the initial ﬁndings at the diag-
nosis of ALL, probably reﬂecting the biological variability of
the disease.23
Concern over misdiagnosis or delayed diagnosis of chil-
dren later found to have ALL has recently been raised,24
particularly with respect to those cases presenting with
musculoskeletal signs and symptoms, especially those mas-
querading as arthritis.25 Misdiagnosis or delayed diagnosis
was not assessed in the patients of this study; however, it is
reasonable to assume that these factors were present in a pro-
portion of our cases, as suggested by the fact that almost 40%
reported musculoskeletal pain.
Limitations in the present report include, but are not lim-
ited to, its relatively small sample size and the fact that the
cross-sectional retrospective design did not allow for collec-
tion of additional data, including percentage of blasts in the
CBC at the diagnosis of ALL, preventing further analysis of
its association with other important clinical and laboratory
variables.
In conclusion, there was remarkable heterogeneity in the
initial CBC data, symptoms and physical examination ﬁnd-
ings in children with ALL. In some cases these data differed
considerably from those traditionally expected; this hetero-
geneity is more  probably multifactorial and can be a surrogate
for other aspects affecting the clinical course of ALL, including
time to diagnosis, different mutations and/or polymorphisms
involved in its pathogenesis, as well as geographic and other
biological inﬂuences. It is important to be aware of this het-
erogeneity, as delayed diagnosis favors disease extension and
organ inﬁltration by leukemic cells, considerably decreasing
the chance for curing this, the most curable of childhood
hematologic cancers.
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